New York is currently home to 4447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/02/2025
Locations: NYU Langone Health, Lake Success, New York
Conditions: Colitis, Ulcerative
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/02/2025
Locations: Local Institution - 0042, New York, New York
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Associated Medical Professionals, Syracuse, New York
Conditions: Non-Muscle Invasive Bladder Neoplasms
Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
Recruiting
The study will compare the effectiveness of two relatively brief and scalable evidence-based interventions: the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), a suicide-specific intervention that helps people prevent suicidal crises from escalating, and Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI), a psychotherapeutic crisis intervention treatment for suicidal adolescents that teaches youth skills to prevent suicidal crises an... Read More
Gender:
ALL
Ages:
Between 12 years and 19 years
Trial Updated:
04/02/2025
Locations: Columbia University Irving Medical Center (CUMC), New York, New York
Conditions: Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Recruiting
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
Recruiting
Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2025
Locations: NYU Langone Health Orthopedic Hospital, New York, New York
Conditions: Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Carcinoma, Non-small-Cell Lung
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: Circuit Clinical - Middletown Medical - 111 Maltese Drive- Site Number : 8400065, Middletown, New York
Conditions: Asthma
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
Recruiting
The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York
Conditions: Advanced Prostate Cancer
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/02/2025
Locations: Empire Dermatology, East Syracuse, New York
Conditions: Plaque Psoriasis
Confocal Laser Endomicroscopy VERification
Recruiting
The goal of this multi-center randomized clinical trial is to evaluate the added value of needle based confocal laser endomicroscopy (nCLE)-imaging to regular diagnostic bronchoscopic peripheral lung lesion analysis on the diagnostic yield in patients with peripheral pulmonary nodules suspect for malignancy. The main question\[s\] it aims to answer are: To determine if the addition of nCLE-imaging to conventional diagnostic bronchoscopic peripheral lung lesion analysis results in an improved d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Montefiore Medical Center, New York, New York
Conditions: Lung Cancer, Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Neoplasm of Lung